A report from EuroEFE / EURACTIV it deals with the damage caused by the low prices of generic and biosimilar medicines in an environment of high inflation, and proposes ideas to make it easier for their contribution to the sustainability of the health system to remain relevant and continuous. In the report participates with her opinion the general director of BioSim, encarna cruz.